8/19/2013

The FDA granted orphan-drug status to Epizyme's EPZ-5676, an experimental treatment for acute leukemia where the myeloid/lymphoid, or mixed-lineage, leukemia with gene rearrangement is caused by chromosomal translocation. Epizyme projects that it could submit the drug, which is in early-stage trials, for FDA approval by 2016.

Related Summaries